STAA — STAAR Surgical Company

STAAR Surgical Company (STAA) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Net Sales: $57.8 million, up from $49 million in Q4 2024.
• China Net Sales: $17.5 million, significantly improved from $7.8 million in Q4 2024, but below expectations due to inventory adjustments.
• Gross Profit Margin: Increased to 75.7% from 64.7% year-over-year, attributed to cost reductions and improved manufacturing efficiencies.
• Operating Expenses: Totaled $66.6 million, including $11.2 million related to the terminated Alcon merger. Excluding these costs, operating expenses were $54.7 million, an 8.2% reduction from the previous year.
• Adjusted EBITDA: Loss of $200,000, an improvement from a loss of $20.8 million in Q4 2024.
• Cash Position: Approximately $187.5 million in cash and equivalents, stable since Q2 2025, with no debt.

2. Strategic Updates and Business Highlights

• Transition to a new leadership structure with Warren Foust and Deborah Andrews as Interim Co-CEOs.
• Focus on stabilizing operations post-Alcon merger discussions, with a renewed emphasis on growth, profitability, and innovation.
• Positive momentum in refractive surgery markets, particularly with the EVO ICL gaining market share as laser vision correction declines.
• Successful launch of EVO+ in China, with plans for expanded commercial availability of the Lioli injector in EMEA.
• Ongoing implementation of Oracle ERP to enhance operational efficiency and decision-making.

3. Forward Guidance and Outlook

• No specific financial guidance for 2026, but expectations for significant sales growth compared to 2025.
• Targeting profitability in FY 2026, driven by increased sales and maintained cost discipline.
• Anticipated slight decrease in gross margins due to higher costs from Swiss manufacturing and increased inventory reserves.
• Cash generation expected to resume in the latter half of 2026, with a projected higher cash balance by year-end.

4. Bad News, Challenges, or Points of Concern

• China Market Dynamics: Despite recovering demand, uncertainties regarding inventory management and macroeconomic conditions remain.
• Sales Disruptions: Distributor inventory adjustments negatively impacted Q4 sales, with concerns about future inventory levels and distributor confidence.
• Competitive Pressures: The market for lens-based procedures is growing, but competition is intensifying, particularly from non-Collamer lenses.
• Operational Challenges: The company faced difficulties in managing inventory levels and visibility in the past, which they are now addressing.

5. Notable Q&A Insights

• Distributor Inventory: Inventory levels have stabilized, with improvements noted in early 2026, suggesting readiness for market recovery.
• Growth Projections: While optimistic about growth, management cautioned against expecting pre-2025 hyper growth levels, aiming instead for steady recovery.
• Innovation Focus: Emphasis on bringing new products to market, with ongoing projects in the pipeline, though specific timelines were not disclosed.
• Organizational Health: Employee morale is reportedly high post-Alcon merger discussions, with no unusual turnover reported.

Overall, STAAR Surgical is positioned for a recovery in 2026, focusing on operational efficiency, market expansion, and innovation, despite facing challenges in inventory management and competitive pressures.